Option period 2 - maintenance services for two (2) government-owned sony MA900 cell sorters to maintain optimal performance in support of the NCI/CCR/vaccine branch and pediatric oncology branch
Active Purchase Order Awarded Last action
- Contract number
- 75N91023P00246
- Awardee
-
Sony Biotechnology Inc. UEI DQF2MP5BTAW7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $134,006
Award facts
- Opportunity
-
- 75N91023Q00013 Solicitation number
- Contract value 40% obligated
-
- $268,012.80 Current, with exercised options
- $335,016.00 Potential, with all options
- Completion date 74% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 811210 Electronic and Precision Equipment Repair and Maintenance
- Set-aside
- No set-aside
- Competition
- 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $67,003 | |
| Exercise an Option | $67,003 | |
| Exercise an Option | $67,003 | |
| Original award | $67,003 |
About this award
The National Cancer Institute awarded a firm fixed-price purchase order to Sony Biotechnology Inc. for maintenance services on two government-owned Sony MA900 cell sorters supporting the NCI's Center for Cancer Research Vaccine Branch and Pediatric Oncology Branch. This contract covers option periods 2 and 3, with a combined ceiling value of $335,016 and an ultimate completion date of February 29, 2028. The work will be performed in Potomac, Maryland, and no small business set-aside was utilized for this procurement.
Sony Biotechnology Inc., a specialized manufacturer of advanced flow cytometry and cell sorting instrumentation based in San Jose, California, has an extensive history of providing scientific equipment and maintenance services to the National Institutes of Health and its constituent institutes. The MA900 cell sorters are critical instruments for the NCI's cancer research programs, enabling researchers to isolate and analyze specific cell populations. As a parent organization with significant federal contracting experience primarily within the Department of Health and Human Services, Sony Biotechnology is well-positioned to maintain optimal performance of these sophisticated research instruments essential to the NCI's vaccine development and pediatric oncology research initiatives.
Quick answers
Who was awarded contract 75N91023P00246?
75N91023P00246 was awarded to Sony Biotechnology Inc. by National Cancer Institute (National Institutes of Health) on March 1, 2023.
How much is contract 75N91023P00246 worth?
The government has obligated $134,006 on 75N91023P00246. Its current value, with exercised options, is $268,013. Its potential value, with all options, is $335,016.
Was contract 75N91023P00246 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award